Abstract
Background Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was denied access to the US market by the Food and Drug Administra......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
